259 related articles for article (PubMed ID: 27713150)
41. IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies.
Bergaggio E; Riganti C; Garaffo G; Vitale N; Mereu E; Bandini C; Pellegrino E; Pullano V; Omedè P; Todoerti K; Cascione L; Audrito V; Riccio A; Rossi A; Bertoni F; Deaglio S; Neri A; Palumbo A; Piva R
Blood; 2019 Jan; 133(2):156-167. PubMed ID: 30455381
[TBL] [Abstract][Full Text] [Related]
42. Suppression of proteasome induces apoptosis in APL cells and increases chemo-sensitivity to arsenic trioxide: Proposing a perception in APL treatment.
Zamani-Moghaddam N; Mousavi FS; Esmaeili S; Yousefi AM; Safaroghli-Azar A; Bashash D
Cancer Treat Res Commun; 2021; 26():100284. PubMed ID: 33387871
[TBL] [Abstract][Full Text] [Related]
43. Doxorubicin-induced death in neuroblastoma does not involve death receptors in S-type cells and is caspase-independent in N-type cells.
Hopkins-Donaldson S; Yan P; Bourloud KB; Muhlethaler A; Bodmer JL; Gross N
Oncogene; 2002 Sep; 21(39):6132-7. PubMed ID: 12203125
[TBL] [Abstract][Full Text] [Related]
44. A possible antineoplastic potential of selective, irreversible proteasome inhibitor, carfilzomib on chemically induced hepatocarcinogenesis in rats.
Mansour MA; Aljoufi MA; Al-Hosaini K; Al-Rikabi AC; Nagi MN
J Biochem Mol Toxicol; 2014 Sep; 28(9):400-6. PubMed ID: 24861196
[TBL] [Abstract][Full Text] [Related]
45. Carfilzomib inhibits the growth of lung adenocarcinoma via upregulation of Gadd45a expression.
Yang F; Liu WW; Chen H; Zhu J; Huang AH; Zhou F; Gan Y; Zhang YH; Ma L
J Zhejiang Univ Sci B; 2020 Jan.; 21(1):64-76. PubMed ID: 31898443
[TBL] [Abstract][Full Text] [Related]
46. Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signaling.
Li H; Yu Y; Zhao Y; Wu D; Yu X; Lu J; Chen Z; Zhang H; Hu Y; Zhai Y; Su J; Aheman A; De Las Casas A; Jin J; Xu X; Shi Z; Woodfield SE; Vasudevan SA; Agarwal S; Yan Y; Yang J; Foster JH
Cancer Lett; 2019 Aug; 457():129-141. PubMed ID: 31100410
[TBL] [Abstract][Full Text] [Related]
47. Novel multi-targeted ErbB family inhibitor afatinib blocks EGF-induced signaling and induces apoptosis in neuroblastoma.
Mao X; Chen Z; Zhao Y; Yu Y; Guan S; Woodfield SE; Vasudevan SA; Tao L; Pang JC; Lu J; Zhang H; Zhang F; Yang J
Oncotarget; 2017 Jan; 8(1):1555-1568. PubMed ID: 27902463
[TBL] [Abstract][Full Text] [Related]
48. Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms.
Yang L; Zhang S; George SK; Teng R; You X; Xu M; Liu H; Sun X; Amin HM; Shi W
Oncotarget; 2015 Jun; 6(17):14953-69. PubMed ID: 25879451
[TBL] [Abstract][Full Text] [Related]
49. Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation.
Okabe S; Tanaka Y; Tauchi T; Ohyashiki K
Ann Hematol; 2019 Mar; 98(3):723-733. PubMed ID: 30430191
[TBL] [Abstract][Full Text] [Related]
50. Proteasome inhibition as a novel mechanism of the proapoptotic activity of γ-secretase inhibitor I in cutaneous T-cell lymphoma.
Biskup E; Kamstrup MR; Manfé V; Gniadecki R
Br J Dermatol; 2013 Mar; 168(3):504-12. PubMed ID: 23445313
[TBL] [Abstract][Full Text] [Related]
51. Ternary Polypeptide Nanoparticles with Improved Encapsulation, Sustained Release, and Enhanced In Vitro Efficacy of Carfilzomib.
Agbana P; Lee MJ; Rychahou P; Kim KB; Bae Y
Pharm Res; 2020 Oct; 37(11):213. PubMed ID: 33025286
[TBL] [Abstract][Full Text] [Related]
52. Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer.
Mehta A; Zhang L; Boufraqech M; Zhang Y; Patel D; Shen M; Kebebew E
Endocr Relat Cancer; 2015 Jun; 22(3):319-29. PubMed ID: 25972243
[TBL] [Abstract][Full Text] [Related]
53. Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines.
Hanke NT; Garland LL; Baker AF
J Cancer Res Clin Oncol; 2016 Mar; 142(3):549-60. PubMed ID: 26385374
[TBL] [Abstract][Full Text] [Related]
54. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
[TBL] [Abstract][Full Text] [Related]
55. Mechanisms of neuroblastoma cell growth inhibition by CARP-1 functional mimetics.
Muthu M; Cheriyan VT; Munie S; Levi E; Frank J; Ashour AE; Singh M; Rishi AK
PLoS One; 2014; 9(7):e102567. PubMed ID: 25033461
[TBL] [Abstract][Full Text] [Related]
56. Novel multiple tyrosine kinase inhibitor ponatinib inhibits bFGF-activated signaling in neuroblastoma cells and suppresses neuroblastoma growth in vivo.
Li H; Wang Y; Chen Z; Lu J; Pan J; Yu Y; Zhao Y; Zhang H; Hu T; Liu Q; Yang J
Oncotarget; 2017 Jan; 8(4):5874-5884. PubMed ID: 27564113
[TBL] [Abstract][Full Text] [Related]
57. Glioma-derived cancer stem cells are hypersensitive to proteasomal inhibition.
Yoo YD; Lee DH; Cha-Molstad H; Kim H; Mun SR; Ji C; Park SH; Sung KS; Choi SA; Hwang J; Park DM; Kim SK; Park KJ; Kang SH; Oh SC; Ciechanover A; Lee YJ; Kim BY; Kwon YT
EMBO Rep; 2017 Jan; 18(1):150-168. PubMed ID: 27993939
[TBL] [Abstract][Full Text] [Related]
58. Doxorubicin induced apoptosis was potentiated by neferine in human lung adenocarcima, A549 cells.
Poornima P; Kumar VB; Weng CF; Padma VV
Food Chem Toxicol; 2014 Jun; 68():87-98. PubMed ID: 24632453
[TBL] [Abstract][Full Text] [Related]
59. A binuclear complex constituted by diethyldithiocarbamate and copper(I) functions as a proteasome activity inhibitor in pancreatic cancer cultures and xenografts.
Han J; Liu L; Yue X; Chang J; Shi W; Hua Y
Toxicol Appl Pharmacol; 2013 Dec; 273(3):477-83. PubMed ID: 24060341
[TBL] [Abstract][Full Text] [Related]
60. Proteasome inhibitors induce apoptosis and reduce viral replication in primary effusion lymphoma cells.
Saji C; Higashi C; Niinaka Y; Yamada K; Noguchi K; Fujimuro M
Biochem Biophys Res Commun; 2011 Dec; 415(4):573-8. PubMed ID: 22074820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
